Oxford Nanopore Technologies is looking into dual listings in London and Hong Kong, according to the South China Morning Post.
As previously disclosed, Bio-Rad's accounting firm needs more time to complete its audit and the company plans to file the form as soon as possible.
The company's stock faced delisting for trading below $1 for 30 consecutive business days in violation of the Nasdaq's requirements.
The firm raised €4.7 million through a conditional placement, and €5.0 million through an unconditional direct subscription.
The molecular diagnostics firm was told on Wednesday that it is again in compliance with a rule calling for a $1 minimum bid on its share price.
The company, a division of BGI Group, sold 40.1 million shares at RMB 13.64 per share for a total of RMB 547 million ($80.6 million) in the offering.
Nasdaq told the firm on Tuesday that its shares failed to maintain a minimum bid price of $1 per share for at least 30 consecutive trading days.
The firm had been notified in November that it failed to meet a listing requirement calling for at least $2.5 million in stockholder equity and faced delisting action.
The firm said that its shares will begin trading on the OTCQB exchange starting on Feb. 22.
The firm was able to maintain a minimum closing bid price of at least $1 per share for at least 10 consecutive business days.
Australia will not be regulating gene editing of plants, animals, and human cell lines as long as no new genetic material is incorporated, reports Nature News.
The Washington Post reports that the US Department of Agriculture told its researchers to label peer-reviewed articles as "preliminary" work.
Researchers have sequenced the genomes of both the coast redwood and the giant sequoia, according to the San Francisco Chronicle.
In PNAS this week: study of epigenetic patterns in mammalian eggs, clonal expansion patterns in CD8+ T cells, and more.